Evofem Biosciences (EVFM) shares new corporate investor slide deck

Rhea-AI Filing Summary

Evofem Biosciences, Inc. reported that it has posted its current corporate slide presentation to the Investors section of its website. The same presentation is being used at various industry and investor conferences to provide updates and summaries of the company’s business.

The slide deck is included as Exhibit 99.1 to this report and is described as having been prepared as of January 12, 2026. Evofem states that it has no obligation to update, supplement, or amend these materials and clarifies that the information in the exhibit is being furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporation by reference into other securities law documents.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001618835 0001618835 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

EVOFEM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36754		20-8527075
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

7770 Regents Road, Suite 113-618

San Diego, California 92122

(Address of principal executive offices)

(858) 550-1900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Evofem Biosciences, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. The Company is posting to the “Investors” portion of its website at www.evofem.com a copy of its current corporate slide presentation. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate presentation prepared as of January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EVOFEM BIOSCIENCES, INC.
Dated: January 12, 2026	By:	/s/ Saundra Pelletier
		Saundra Pelletier
		Chief Executive Officer

FAQ

What did Evofem Biosciences (EVFM) disclose in this 8-K?

Evofem Biosciences disclosed that it has posted a current corporate slide presentation to the Investors section of its website and furnished the same materials as Exhibit 99.1.

Where can investors find Evofem Biosciences' latest corporate presentation?

Investors can access Evofem Biosciences' latest corporate presentation on the Investors portion of its website at www.evofem.com, and it is also included as Exhibit 99.1 to this report.

What is included in Exhibit 99.1 for Evofem Biosciences (EVFM)?

Exhibit 99.1 contains a corporate presentation for Evofem Biosciences that provides updates and summaries of its business, prepared as of January 12, 2026.

Is the Evofem Biosciences corporate presentation considered filed under the Exchange Act?

No. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to its liabilities.

Will Evofem Biosciences update its posted corporate presentation over time?

Evofem Biosciences notes that it undertakes no obligation to update, supplement, or amend the materials attached as Exhibit 99.1.

Who signed this Evofem Biosciences report?

The report was signed on behalf of Evofem Biosciences, Inc. by Saundra Pelletier, Chief Executive Officer.